Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PDE5A | O76074 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7388781 | 0.90 | ALDH1A1 (0.63) | ALDH1A1KMT2ATSHRCYP2D6LMNA | |
| SCHEMBL6446698 | 0.90 | ALDH1A1 (0.63) | ALDH1A1KMT2ATSHRCYP2D6LMNA | |
| SCHEMBL3578634 | 0.89 | ALDH1A1 (0.64) | ALDH1A1KMT2ATSHRLMNAPDE5A | |
| SCHEMBL7388778 | 0.89 | ALDH1A1 (0.61) | ALDH1A1KMT2ATSHRCYP2D6LMNA | |
| SCHEMBL6447545 | 0.88 | ALDH1A1 (0.64) | ALDH1A1KMT2ATSHRCYP2D6LMNA | |
| SCHEMBL6443522 | 0.87 | ALDH1A1 (0.63) | ALDH1A1KMT2ATSHRCYP2D6LMNA | |
| SCHEMBL6446145 | 0.83 | ALDH1A1 (0.60) | ALDH1A1KMT2ATSHRCYP2D6LMNA | |
| SCHEMBL5827170 | 0.83 | KMT2A (0.67) | ALDH1A1KMT2ATSHRCYP2D6PDE5A | |
| SCHEMBL6446723 | 0.82 | ALDH1A1 (0.59) | ALDH1A1KMT2ATSHRCYP2D6LMNA | |
| SCHEMBL2408689 | 0.82 | ALDH1A1 (1.00) | ALDH1A1KMT2ATSHRCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1440709-B1 | Combinations comprising cGMP PDE5 inhibitors. | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | LEE ANDREW G (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1149579-A2 | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1129706-A2 | Use of cGMP PDE5 inhibitors for the treatment of neuropathy | Pfizer Limited (GB) | 2001-09-05 | — | — | EP | disclosed |
| EP-1125582-A2 | Use of estrogen agonists / antagonists for the treatment of sexual dysfunction | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1123296-A1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2001-08-16 | — | — | EP | disclosed |
| WO-2001051042-A2 | TREATMENT OF DIABETIC ULCERS | PFIZER LIMITED (GB) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-1092718-A1 | 2-(2-Alkoxy-5-heterocyclylsulphonylphenyl)purin-6-ones as phosphodiesterase inhibitors | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000024745-A1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2000-05-04 | — | — | WO | disclosed |
| EP-0995751-A2 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | ALDH1A1 758/4885KMT2A 4553/4885TSHR 2771/4885 |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | PDE3B, PDE3A, SHBG | ALDH1A1 2502/4885KMT2A 4667/4885TSHR 281/4885 |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | ALDH1A1 848/4885KMT2A 3472/4885TSHR 2480/4885 |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | ALDH1A1 848/4885KMT2A 3472/4885TSHR 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.